You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海王生物(000078.SZ):HW130注射液獲美國FDA批准進入人體臨牀試驗
格隆匯 01-17 17:54

格隆匯1月17日丨海王生物(000078.SZ)公佈,公司全資子公司深圳海王醫藥科技研究院有限公司(海王醫藥研究院)2020117日收到美國食品藥品監督管理局(美國FDA”)簽發的書面通知,批准海王醫藥研究院自主研發、具有自主知識產權的新型腫瘤血管阻斷劑HW130射液在美國開展I期藥物人體臨牀試驗。

HW130注射液是海王醫藥研究院自主研發、具有自主知識產權的新型腫瘤血管阻斷劑。經綜合的臨牀前研究考察,HW130注射液具有顯著的腫瘤血管破壞作用以及顯著降低腫瘤治療患者死亡率的作用,顯著提升腫瘤綜合治療的臨牀效益;對正常器官組織的損傷輕微,具有高度的靶向性與安全性。該項目的開發可一定程度上解決臨牀未被滿足的臨牀需求,具有較大的開發潛力與市場空間。

目前該項目已獲中國、美國化合物發明專利授權。

據公司瞭解目前國內外無同類藥物上市,同類藥物多處於臨牀前及臨牀研究等不同階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account